Valuation: MediWound Ltd.

Market Cap 168M 144M 135M 123M 232M 16B 235M 1.59B 619M 8.07B 630M 616M 26.73B P/E 2026 *
-5.93x
P/E 2027 * -5.91x
Enterprise Value 168M 144M 135M 123M 232M 16B 235M 1.59B 619M 8.07B 630M 616M 26.73B EV / Sales 2026 *
7.09x
EV / Sales 2027 * 5.28x
Free-Float
84.04%
Yield 2026 *
-
Yield 2027 * -
1 day-1.12%
1 week-5.35%
Current month-8.57%
1 month-10.66%
3 months-22.60%
6 months-26.02%
Current year-30.07%
1 week 12.85
Extreme 12.85
13.78
1 month 12.85
Extreme 12.85
14.87
Current year 12.85
Extreme 12.85
19.7
1 year 12.85
Extreme 12.85
20.3
3 years 7.1
Extreme 7.1
24
5 years 7.1
Extreme 7.1
28.07
10 years 7.1
Extreme 7.1
60.06
Manager TitleAgeSince
Chief Executive Officer 52 2022-06-29
Director of Finance/CFO 54 2023-05-13
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 72 2017-05-17
Chairman 69 2017-10-24
Director/Board Member 68 2020-04-26
Change 5-day change 1-year change 3-year change Capi.($)
-1.12%-5.35%-25.16%+46.21% 168M
+0.83%+3.01%+45.82%+0.52% 82.73B
+2.68%+29.00%-19.83%-34.19% 57.94B
+13.94%+147.72%+515.25%+39.34% 55.45B
+0.76%+2.39%+0.08%+35.11% 52.57B
+1.86%+3.13%+11.49%+174.36% 48.94B
+1.73%+4.06%+62.20%-16.36% 32.23B
+1.85%+5.24%+53.30%+103.47% 25.94B
+0.60%+4.98%+0.65%+188.89% 22.1B
+3.89%+1.08%+61.82%+112.10% 16.55B
Average +2.69%+15.68%+70.56%+64.95% 39.46B
Weighted average by Cap. +3.30%+21.97%+91.73%+47.69%

Financials

2026 *2027 *
Net sales 23.67M 20.29M 19.01M 17.36M 32.77M 2.26B 33.09M 224M 87.29M 1.14B 88.89M 86.96M 3.77B 31.81M 27.25M 25.54M 23.33M 44.02M 3.03B 44.46M 301M 117M 1.53B 119M 117M 5.07B
Net income -29.11M -24.94M -23.37M -21.35M -40.29M -2.78B -40.69M -276M -107M -1.4B -109M -107M -4.64B -31.82M -27.27M -25.55M -23.34M -44.04M -3.03B -44.48M -301M -117M -1.53B -119M -117M -5.07B
Net Debt - -
Logo MediWound Ltd.
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Employees
121
Date Price Change Volume
26-08-25 US$12.91 -0.69% 33,013
26-08-24 US$13.00 -1.59% 101,561
26-08-21 US$13.21 +0.72% 79,832
26-08-20 US$13.12 -3.50% 81,387
26-08-19 US$13.59 -0.37% 53,611
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
13.00USD
Average target price
29.83USD
Spread / Average Target
+129.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDWD Stock